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Malignancies are associated with an increased risk 
of thromboembolic vascular events, that can involve 
both the venous and arterial sites. The venous 
thromboembolism (VTE) risk may increase in up to 
13% in patients on active chemotherapy. VTE is known 
to be the second-leading cause of death in patients 
with malignancy. Moreover, when cancer-related 
deaths are excluded, VTE becomes the leading cause 
of death in cancer patients along with infection (9.2%) 
[1]. Given the reported thrombosis-related mortality 
rates along with high costs and extended hospitalisa- 
tion, appropriate risk stratification and prevention of 
thrombosis need to be carefully determined in the 
setting of supportive cancer treatment.  
Multiple myeloma (MM) is a clonal plasma cell 
disorder accounting for ~1% of all malignancies and 
>10% of hematological malignancies in the United 
States [2]. As well as other malignancies, MM is 
remained at an increased risk of VTE. The incidence of 
VTE in myeloma patients is mainly reported by studies 
in a therapy-related context. The VTE rate was found to 
be 12% in newly diagnosed MM patients treated with 
lenalidomide plus high-dose dexamethasone (no 
thromboprophylaxis), whereas it was only 2.27% in 
aspirin prophylaxis arm and 1.2% in low-molecular 
weight heparin (LMWH) arm [3]. 
International Staging System (ISS), utilizing a 
combination of serum β2 microglobulin and serum 
albumin has been developed in 2005 [4]. ISS provides 
a reproduciple three-stage classification for myeloma 
patients. Low serum albumin levels (<3.5 g/dL) are 
associated with advanced disease status, high tumor 
burden and low median survival rates. However, to the 
best of our knowledge, hypoalbuminemia is not being 
described as a predictor of VTE in patients with MM. 
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Bever et al. have very recently reported that among 
the 824 available patients with immunoglobulin light 
chain (AL) amyloidosis, 7% of the patients had 
developed at least one VTE episode and 80% of them 
had vascular events within one year prior to or 
following diagnosis. The only significant risk factor for 
predicting VTE was reported as having a serum 
albumin level of <3 g/dL versus >4 g/dL. A subgroup 
analysis of 382 patients with nephrotic-range 
proteinuria (>3.5 g/day) associated with a higher VTE 
rate (9.7%). Interestingly, after the reanalysis, 
hypoalbuminemia did not reveal any significance with 
the development of VTE risk [5]. The association of 
serum albumin levels and risk of VTE is conflicting, 
whereas the ratio of proteinuria to serum albumin level 
is likely to be a stronger predictor of VTE in patients 
with nephrotic syndrome than serum albumin levels [6, 
7].  
The pathophysiology of VTE in AL amyloidosis is 
not exactly elucidated, but it seems to be multifactorial. 
In a recent retrospective analysis, nearly 60% of the 
patients complicated with VTE had primary renal 
involvement [5]. Alterations in plasma levels of pro- and 
anti-coagulant serum proteins are involved in the 
pathophysiology of VTE in nephrotic syndrome [8]. 
Similarly, the renal loss of antithrombin III [9], protein C, 
and/or protein S along with albumin should be 
expected in AL amyloidosis patients with renal 
involvement. One can speculate that the loss of natural 
anticoagulants in AL patients with renal involvement 
may explain, at least partly, why hypoalbuminemia is 
linked with higher rates of VTE in AL amyloidosis and 
not in MM. However, in contrast with this hypothesis, 
the impact of hypoalbuminemia for predicting VTE risk 
did not continue when the statistical analyses were 
repeated for only VTE patients with nephrotic range 
proteinuria [5].  
In a large, retrospective study including 298 
consecutive patients with nephrotic syndrome, not only 
the risk of VTE, but also the risk of arterial thrombotic 
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events is remarkably elevated, especially within the first 
6 months of diagnosis [6]. Antithrombin III deficiency is 
manifested primarily by recurrent VTE, whereas arterial 
thrombosis is reported less frequently [10]. Cardiac 
involvement in AL amyloidosis is also commonly 
associated with arterial thromboses [11]. In Bever et 
al.’s large scale cohort, a quarter of VTE patients had 
primary cardiac involvement [1]. Aspirin is classically 
more effective in preventing arterial thrombosis, but its 
efficacy in VTE remains controversial [12, 13]. 
Bagratuni et al. had reported that among 200 
unselected MM patients who were treated with a 
lenalidomide-based regimen, all VTEs were detected in 
patients under aspirin prophylaxis [14]. Similarly, in a 
large real-life observational study including 524 MM 
patients, VTE episodes were observed 7% on aspirin, 
whereas only 3% on LMWH, and none on vitamin K 
antagonists [15].  
In conclusion, hypoalbuminemia as a promising risk 
factor of VTE in AL amyloidosis, needs to be further 
evaluated with prospective studies. Not only VTE 
episodes, but also arterial vascular thrombotic events 
and cardiac involvement should be carefully evaluated. 
The individual patient is at the center and optimal 
patient outcome should be its goal. 
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